Patents by Inventor Mercedes Delgado

Mercedes Delgado has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20230116093
    Abstract: Provided herein are Diaminopyrimidine Compounds having the following structures: wherein R1, R2, R3, and R4 are as defined herein, compositions comprising an effective amount of a Diaminopyrimidine Compound, and methods for treating or preventing liver fibrotic disorders or a condition treatable or preventable by inhibition of a JNK pathway.
    Type: Application
    Filed: March 29, 2022
    Publication date: April 13, 2023
    Inventors: Brydon L. Bennett, Mercedes Delgado, Jan Elsner, Paul Erdman, Robert Hilgraf, Laurie Ann LeBrun, Meg McCarrick, Mehran F. Moghaddam, Mark A. Nagy, Stephen Norris, David A. Paisner, William J. Romanow, Yoshitaka Satoh, Marianne Sloss, Jayashree Tikhe, Won Hyung Yoon
  • Patent number: 11325890
    Abstract: Provided herein are Diaminopyrimidine Compounds having the following structures: wherein R1, R2, R3, and R4 are as defined herein, compositions comprising an effective amount of a Diaminopyrimidine Compound, and methods for treating or preventing liver fibrotic disorders or a condition treatable or preventable by inhibition of a JNK pathway.
    Type: Grant
    Filed: December 29, 2020
    Date of Patent: May 10, 2022
    Assignee: Signal Pharmaceuticals, LLC
    Inventors: Mercedes Delgado, Jan Elsner, Paul Erdman, Robert Hilgraf, Mark A. Nagy, Stephen Norris, David A. Paisner, Yoshitaka Satoh, Marianne Sloss, Jayashree Tikhe, Won Hyung Yoon
  • Publication number: 20210114992
    Abstract: Provided herein are Diaminopyrimidine Compounds having the following structures: wherein R1, R2, R3, and R4 are as defined herein, compositions comprising an effective amount of a Diaminopyrimidine Compound, and methods for treating or preventing liver fibrotic disorders or a condition treatable or preventable by inhibition of a JNK pathway.
    Type: Application
    Filed: December 29, 2020
    Publication date: April 22, 2021
    Inventors: Mercedes Delgado, Jan Elsner, Paul Erdman, Robert Hilgraf, Mark A. Nagy, Stephen Norris, David A. Paisner, Yoshitaka Satoh, Marianne Sloss, Jayashree Tikhe, Won Hyung Yoon
  • Patent number: 10919865
    Abstract: Provided herein are Diaminopyrimidine Compounds having the following structures: wherein R1, R2, R3, and R4 are as defined herein, compositions comprising an effective amount of a Diaminopyrimidine Compound, and methods for treating or preventing liver fibrotic disorders or a condition treatable or preventable by inhibition of a JNK pathway.
    Type: Grant
    Filed: March 4, 2019
    Date of Patent: February 16, 2021
    Assignee: SIGNAL PHARMACEUTICALS, LLC
    Inventors: Mercedes Delgado, Jan Elsner, Paul Erdman, Robert Hilgraf, Mark A. Nagy, Stephen Norris, David A. Paisner, Yoshitaka Satoh, Marianne Sloss, Jayashree Tikhe, Won Hyung Yoon
  • Publication number: 20190194144
    Abstract: Provided herein are Diaminopyrimidine Compounds having the following structures: wherein R1, R2, R3, and R4 are as defined herein, compositions comprising an effective amount of a Diaminopyrimidine Compound, and methods for treating or preventing liver fibrotic disorders or a condition treatable or preventable by inhibition of a JNK pathway.
    Type: Application
    Filed: March 4, 2019
    Publication date: June 27, 2019
    Inventors: Mercedes Delgado, Jan Elsner, Paul Erdman, Robert Hilgraf, Mark A. Nagy, Stephen Norris, David A. Paisner, Yoshitaka Satoh, Marianne Sloss, Jayashree Tikhe, Won Hyung Yoon
  • Patent number: 10266500
    Abstract: Provided herein are Diaminopyrimidine Compounds having the following structures: wherein R1, R2, R3, and R4 are as defined herein, compositions comprising an effective amount of a Diaminopyrimidine Compound, and methods for treating or preventing liver fibrotic disorders or a condition treatable or preventable by inhibition of a JNK pathway.
    Type: Grant
    Filed: June 28, 2018
    Date of Patent: April 23, 2019
    Assignee: Signal Pharmaceuticals, LLC
    Inventors: Brydon L. Bennett, Mercedes Delgado, Jan Elsner, Paul Erdman, Robert Hilgraf, Laurie Ann LeBrun, Meg McCarrick, Mark A. Nagy, Stephen Norris, David A. Paisner, Yoshitaka Satoh, Marianne Sloss, Jayashree Tikhe, Won Hyung Yoon
  • Publication number: 20180305322
    Abstract: Provided herein are Diaminopyrimidine Compounds having the following structures: wherein R1, R2, R3, and R4 are as defined herein, compositions comprising an effective amount of a Diaminopyrimidine Compound, and methods for treating or preventing liver fibrotic disorders or a condition treatable or preventable by inhibition of a JNK pathway.
    Type: Application
    Filed: June 28, 2018
    Publication date: October 25, 2018
    Inventors: Brydon L. Bennett, Mercedes Delgado, Jan Elsner, Paul Erdman, Robert Hilgraf, Laurie Ann LeBrun, Meg McCarrick, Mark A. Nagy, Stephen Norris, David A. Paisner, Yoshitaka Satoh, Marianne Sloss, Jayashree Tikhe, Won Hyung Yoon
  • Patent number: 10040770
    Abstract: Provided herein are Diaminopyrimidine Compounds having the following structures: wherein R1, R2, R3, and R4 are as defined herein, compositions comprising an effective amount of a Diaminopyrimidine Compound, and methods for treating or preventing liver fibrotic disorders or a condition treatable or preventable by inhibition of a JNK pathway.
    Type: Grant
    Filed: June 7, 2017
    Date of Patent: August 7, 2018
    Assignee: Signal Pharmaceuticals, LLC
    Inventors: Mercedes Delgado, Jan Elsner, Paul Erdman, Robert Hilgraf, Laurie Ann LeBrun, Meg McCarrick, Mark A. Nagy, Stephen Norris, David A. Paisner, Yoshitaka Satoh, Marianne Sloss, Jayashree Tikhe, Won Hyung Yoon
  • Patent number: 9783505
    Abstract: Provided herein are diaminopyrimidyl Compounds having the following structures: wherein X, L, R1, and R2 are as defined herein, compositions comprising an effective amount of a Diaminopyrimidyl Compound, and methods for treating or preventing PKC-theta-mediated disorders, or a condition treatable or preventable by inhibition of a kinase, for example, PKC-theta.
    Type: Grant
    Filed: August 19, 2016
    Date of Patent: October 10, 2017
    Assignee: Signal Pharmaceuticals, LLC
    Inventors: Patrick Papa, Brian Edwin Cathers, Andrew Antony Calabrese, Brandon Wade Whitefield, Brydon Bennett, Daniel Cashion, Deborah Mortensen, Dehua Huang, Eduardo Torres, Jason Parnes, John Sapienza, Joshua Hansen, Katerina Leftheris, Matthew Correa, Maria Mercedes Delgado, Raj K. Raheja, Sogole Bahmanyar, Sayee Hegde, Stephen Norris, Veronique Plantevin-Krenitsky
  • Publication number: 20170267647
    Abstract: Provided herein are Diaminopyrimidine Compounds having the following structures: wherein R1, R2, R3, and R4 are as defined herein, compositions comprising an effective amount of a Diaminopyrimidine Compound, and methods for treating or preventing liver fibrotic disorders or a condition treatable or preventable by inhibition of a JNK pathway.
    Type: Application
    Filed: June 7, 2017
    Publication date: September 21, 2017
    Inventors: Mercedes Delgado, Jan Elsner, Paul Erdman, Robert Hilgraf, Laurie Ann LeBrun, Meg McCarrick, Mark A. Nagy, Stephen Norris, David A. Paisner, Yoshitaka Satoh, Marianne Sloss, Jayashree Tikhe, Won Hyung Yoon
  • Patent number: 9701643
    Abstract: Provided herein are Diaminopyrimidine Compounds having the following structures: wherein R1, R2, R3, and R4 are as defined herein, compositions comprising an effective amount of a Diaminopyrimidine Compound, and methods for treating or preventing liver fibrotic disorders or a condition treatable or preventable by inhibition of a JNK pathway.
    Type: Grant
    Filed: July 31, 2015
    Date of Patent: July 11, 2017
    Assignee: Signal Pharmaceuticals, LLC
    Inventors: Brydon L. Bennett, Mercedes Delgado, Jan Elsner, Paul Erdman, Robert Hilgraf, Laurie Ann LeBrun, Meg McCarrick, Mehran F. Moghaddam, Mark A. Nagy, Stephen Norris, David A. Paisner, William J. Romanow, Yoshitaka Satoh, Marianne Sloss, Jayashree Tikhe, Won Hyung Yoon
  • Patent number: 9556126
    Abstract: Provided herein are diaminopyrimidyl Compounds having the following structures: wherein X, L, R1, and R2 are as defined herein, compositions comprising an effective amount of a Diaminopyrimidyl Compound, and methods for treating or preventing PKC-theta-mediated disorders, or a condition treatable or preventable by inhibition of a kinase, for example, PKC-theta.
    Type: Grant
    Filed: December 19, 2014
    Date of Patent: January 31, 2017
    Assignee: Signal Pharmaceuticals, LLC
    Inventors: Patrick Papa, Brian Edwin Cathers, Andrew Antony Calabrese, Brandon Wade Whitefield, Brydon Bennett, Daniel Cashion, Deborah Mortensen, Dehua Huang, Eduardo Torres, Jason Parnes, John Sapienza, Joshua Hansen, Katerina Leftheris, Matthew Correa, Maria Mercedes Delgado, Raj K. Raheja, Sogole Bahmanyar, Sayee Hegde, Stephen Norris, Veronique Plantevin-Krenitsky
  • Publication number: 20160354374
    Abstract: Provided herein are diaminopyrimidyl Compounds having the following structures: wherein X, L, R1, and R2 are as defined herein, compositions comprising an effective amount of a Diaminopyrimidyl Compound, and methods for treating or preventing PKC-theta-mediated disorders, or a condition treatable or preventable by inhibition of a kinase, for example, PKC-theta.
    Type: Application
    Filed: August 19, 2016
    Publication date: December 8, 2016
    Inventors: Patrick Papa, Brian Edwin Cathers, Andrew Antony CALABRESE, Brandon Wade WHITEFIELD, Brydon BENNETT, Daniel CASHION, Deborah MORTENSEN, Dehua HUANG, Eduardo TORRES, Jason PARNES, John SAPIENZA, Joshua HANSEN, Katerina LEFTHERIS, Matthew CORREA, Maria Mercedes DELGADO, Raj K. RAHEJA, Sogole BAHMANYAR, Sayee HEGDE, Stephen NORRIS, Veronique PLANTEVIN-KRENITSKY
  • Publication number: 20150336901
    Abstract: Provided herein are Diaminopyrimidine Compounds having the following structures: wherein R1, R2, R3, and R4 are as defined herein, compositions comprising an effective amount of a Diaminopyrimidine Compound, and methods for treating or preventing liver fibrotic disorders or a condition treatable or preventable by inhibition of a JNK pathway.
    Type: Application
    Filed: July 31, 2015
    Publication date: November 26, 2015
    Applicant: SIGNAL PHARMACEUTICALS, LLC
    Inventors: Brydon L. Bennett, Mercedes Delgado, Jan Elsner, Paul Erdman, Robert Hilgraf, Laurie Ann LeBrun, Meg McCarrick, Mehran F. Moghaddam, Mark A. Nagy, Stephen Norris, David A. Paisner, William J. Romanow, Yoshitaka Satoh, Marianne Sloss, Jayashree Tikhe, Won Hyung Yoon
  • Patent number: 9156798
    Abstract: Provided herein are diaminopyrimidyl Compounds having the following structures: wherein X, L, R1, and R2 are as defined herein, compositions comprising an effective amount of a Diaminopyrimidyl Compound, and methods for treating or preventing PKC-theta-mediated disorders, or a condition treatable or preventable by inhibition of a kinase, for example, PKC-theta.
    Type: Grant
    Filed: April 7, 2015
    Date of Patent: October 13, 2015
    Assignee: Signal Pharmaceuticals, LLC
    Inventors: Sogole Bahmanyar, Andrew Antony Calabrese, Daniel Cashion, Brian Edwin Cathers, Matthew Correa, Maria Mercedes Delgado, Joshua Hansen, Sayee Hegde, Dehua Huang, Katerina Leftheris, Deborah Mortensen, Stephen Norris, Patrick Papa, Jason Parnes, Veronique Plantevin-Krenitsky, Raj Kumar Raheja, John Sapienza, Eduardo Torres, Brandon Wade Whitefield
  • Patent number: 9139534
    Abstract: Provided herein are Diaminopyrimidine Compounds having the following structures: wherein R1, R2, R3, and R4 are as defined herein, compositions comprising an effective amount of a Diaminopyrimidine Compound, and methods for treating or preventing liver fibrotic disorders or a condition treatable or preventable by inhibition of a JNK pathway.
    Type: Grant
    Filed: April 20, 2012
    Date of Patent: September 22, 2015
    Assignee: Signal Pharmaceuticals, LLC
    Inventors: Brydon L. Bennett, Jan Elsner, Paul Erdman, Robert Hilgraf, Laurie Ann LeBrun, Meg McCarrick, Mehran F. Moghaddam, Mark A. Nagy, Stephen Norris, David A. Paisner, Marianne Sloss, William J. Romanow, Yoshitaka Satoh, Jayashree Tikhe, Won Hyung Yoon, Mercedes Delgado
  • Publication number: 20150246890
    Abstract: Provided herein are diaminopyrimidyl Compounds having the following structures: wherein X, L, R1, and R2 are as defined herein, compositions comprising an effective amount of a Diaminopyrimidyl Compound, and methods for treating or preventing PKC-theta-mediated disorders, or a condition treatable or preventable by inhibition of a kinase, for example, PKC-theta.
    Type: Application
    Filed: April 7, 2015
    Publication date: September 3, 2015
    Inventors: Sogole BAHMANYAR, Andrew Antony CALABRESE, Daniel CASHION, Brian Edwin CATHERS, Matthew CORREA, Maria Mercedes DELGADO, Joshua HANSEN, Sayee HEGDE, Dehua HUANG, Katerina LEFTHERIS, Deborah MORTENSEN, Stephen NORRIS, Patrick PAPA, Jason PARNES, Veronique PLANTEVIN-KRENITSKY, Raj Kumar RAHEJA, John SAPIENZA, Eduardo TORRES, Brandon Wade WHITEFIELD
  • Publication number: 20150175557
    Abstract: Provided herein are diaminopyrimidyl Compounds having the following structures: wherein X, L, R1, and R2 are as defined herein, compositions comprising an effective amount of a Diaminopyrimidyl Compound, and methods for treating or preventing PKC-theta-mediated disorders, or a condition treatable or preventable by inhibition of a kinase, for example, PKC-theta.
    Type: Application
    Filed: December 19, 2014
    Publication date: June 25, 2015
    Inventors: Patrick Papa, Brian Edwin Cathers, Andrew Antony CALABRESE, Brandon Wade WHITEFIELD, Brydon BENNETT, Daniel CASHION, Deborah MORTENSEN, Dehua HUANG, Eduardo TORRES, Jason PARNES, John SAPIENZA, Joshua HANSEN, Katerina LEFTHERIS, Matthew CORREA, Maria Mercedes DELGADO, Neil RAHEJA, Sami BAHMANYAR, Sayee HEGDE, Stephen NORRIS, Veronique PLANTEVIN-KRENITSKY
  • Patent number: 8383634
    Abstract: Provided herein are Heteroaryl Compounds having the following structure: wherein R1, R3, R4, L, X, Y, A and B are as defined herein, compositions comprising an effective amount of a Heteroaryl Compound and methods for treating or preventing cancer, inflammatory conditions, immunological conditions, metabolic conditions and conditions treatable or preventable by inhibition of a kinase pathway comprising administering an effective amount of a Heteroaryl Compound to a patient in need thereof.
    Type: Grant
    Filed: May 23, 2011
    Date of Patent: February 26, 2013
    Assignee: Signal Pharmaceuticals, LLC
    Inventors: Deborah Sue Mortensen, Maria Mercedes Delgado Mederos, John Joseph Sapienza, Ronald J. Albers, Steven Spencer Clareen, Kimberly Lyn Schwarz, Jason Simon Parnes, Jennifer R. Riggs, Patrick William Papa, Sayee Gajanan Hegde, Jeffrey Mark McKenna
  • Patent number: 8372976
    Abstract: Provided herein are Heteroaryl Compounds having the following structure: wherein R1, R2, L, X, Y, Z, Q, A and B are as defined herein, compositions comprising an effective amount of a Heteroaryl Compound and methods for treating or preventing cancer, inflammatory conditions, immunological conditions, metabolic conditions and conditions treatable or preventable by inhibition of a kinase pathway comprising administering an effective amount of a Heteroaryl Compound to a patient in need thereof.
    Type: Grant
    Filed: June 9, 2011
    Date of Patent: February 12, 2013
    Assignee: Signal Pharmaceuticals, LLC
    Inventors: Deborah Sue Mortensen, Maria Mercedes Delgado Mederos, John Joseph Sapienza, Ronald J. Albers, Branden G. Lee, Roy Leonard Harris, III, Graziella Isabel Shevlin, Dehua Huang, Kimberly Lyn Schwarz, Garrick K. Packard, Jason Simon Parnes, Patrick William Papa, Lida Radnia Tehrani, Sophie Perrin-Ninkovic, Jennifer R. Riggs